<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00866749</url>
  </required_header>
  <id_info>
    <org_study_id>2006-0375</org_study_id>
    <secondary_id>NCI-2012-01650</secondary_id>
    <nct_id>NCT00866749</nct_id>
  </id_info>
  <brief_title>Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma</brief_title>
  <official_title>Augmented Berlin-Frankfurt-Munster Therapy for Adolescents/Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives:

      A. Primary objective:

      1 To assess the feasibility and the effectiveness of pediatric type therapy (augmented BFM)
      in patients age 12 through 40 with untreated precursor-B or T acute lymphoblastic leukemia
      (ALL) or lymphoblastic lymphoma (LL).

      B. Secondary objective:

        1. To evaluate the prognostic significance of minimal residual disease in bone marrow
           samples at the end of induction and at the end of consolidation in this group of
           patients.

        2. To prospectively evaluate gene hypermethylation status in this group of patients.

        3. To prospectively analyze asparaginase activity and anti-asparaginase antibody formation
           in this population of patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Induction:

      During Induction, you will receive augmented Berlin-Frankfurt-Munster chemotherapy, which is
      made up of a combination of Cerubidine®, Daunorubicin Hydrochloride (daunorubicin), Oncovin®
      (vincristine), prednisone, dexamethasone, Oncaspar® (PEG Asparaginase), and MTX amethopterin
      (methotrexate). All of these drugs are designed to interfere with the multiplication of
      cancer cells to cause them to die and to keep the cancer from coming back.

      If you are found to be eligible to take part in this study, on Day 1 or during the spinal tap
      procedure, you will be given cytarabine as an injection in your spinal fluid. Within 3 days,
      you will begin the Induction course, which will last for 4 weeks.

      Daunorubicin and vincristine will be given through a needle in your vein on Days 1, 8,15, and
      22. During the first week of therapy, you will be given 1 infusion of PEG Asparaginase by
      vein. You will take prednisone by mouth on Days 1-28. Methotrexate will be injected into your
      spinal fluid on Weeks 2 and 5 during your spinal tap. Cerebrospinal fluid (CSF) studies will
      be sent with each spinal tap to test the fluid for leukemia. If there is disease in your
      spinal fluid before starting the treatment, you will be given additional methotrexate doses
      once a week until there is no disease present. You will continue to receive methotrexate in
      spinal taps every other week for 8 doses, then monthly for 6 doses.

      Blood (about 3 teaspoons) will be drawn multiple times during the study for routine tests.
      You will have a bone marrow aspirate or biopsy on Days 15 and 29 and then as needed to
      confirm remission.

      If you have less than 5% immature cells in the bone marrow, 1 week after Induction, you will
      continue treatment with Consolidation 1. If you achieved remission after 4 weeks of Induction
      treatment, you will then have treatment with Consolidation 1, which will be discussed in a
      separate informed consent document.

      If you have LL and had no bone marrow involvement at screening, you will have a chest x-ray,
      CT scans, and PET scans to measure the disease. Consolidation 1 and other phases of
      chemotherapy will be discussed in a separate informed consent document.

      If you still have more than 5% leukemia cells in the bone marrow after Induction therapy, you
      will receive 2 extra weeks of therapy called &quot;Extended Induction&quot; before going to the next
      phase of therapy. You will receive daunorubicin by vein on Day 1. You will receive
      vincristine on Weeks 1 and 2 by vein. You will take prednisone by mouth on Days 1-14. You
      will receive PEG Asparaginase by vein in the first week of the Extended Induction. Blood
      (about 3 teaspoons) will be drawn weekly during the Extended Induction period for routine
      tests.

      At the end of the Extended Induction period, you will have a physical exam and a bone marrow
      aspirate or biopsy to learn your response to treatment.

      After Extended Induction, if the disease is in remission, then you will have 1 course of
      Consolidation 1, 2 courses of Consolidation 2, and 2 courses of Consolidation 3 before
      proceeding to Maintenance therapy. A separate discussion and informed consent document for
      Consolidation and Maintenance will be provided.

      Length of Study:

      You may remain on study for as long as you are benefiting. However, if after Extended
      Induction, the disease is not in remission, you will be taken off study, and your doctor will
      discuss other treatment options with you.

      You may be taken off study if the disease gets worse or comes back during treatment,
      intolerable side effects occur, new information becomes available to your study doctor, if
      your doctor thinks it is in your best interest, or if you do not attend your appointments,
      which are scheduled at least once every 3 months.

      This is an investigational study. The chemotherapy drugs used in this study are FDA approved
      and commercially available. Up to 125 patients will take part in this study. All will be
      enrolled at MD Anderson.

      Consolidation and Maintenance:

      During Consolidation, you will receive cyclophosphamide, cytarabine, 6-mercaptopurine,
      vincristine, PEG asparaginase, methotrexate, doxorubicin, 6-thioguanine, and dexamethasone.
      During Maintenance, you will receive, vincristine, dexamethasone, 6-mercaptopurine, and
      methotrexate. All of these drugs are designed to interfere with the multiplication of cancer
      cells to cause them to die and to keep the cancer from coming back.

      If you achieved remission after 4 weeks of induction treatment, you will have treatment with
      Consolidation 1, Consolidation 2, Consolidation 3 (Parts A and B), and then you will proceed
      to Maintenance therapy.

      If the level of blast cells in your blood is above a certain level at Day 15 of Induction but
      you achieved complete remission by Day 29, or if you achieved remission after 6 weeks of
      induction plus extended induction, then you will receive 1 course of Consolidation 1, 2
      courses of Consolidation 2, 2 courses of Consolidation 3 (Parts A and B), and then you will
      proceed to maintenance therapy.

      Consolidation 1 will last for 8 weeks (2 months). You will receive cyclophosphamide through a
      needle in your vein on Weeks 1 and 5. Cytarabine will be given as an injection just beneath
      the skin or by vein on or around Days 1-4 and Days 8-11 of each month. 6-Mercaptopurine will
      be taken by mouth on Days 1-14 of each month. Vincristine will be given by vein on Weeks 3-4
      of each month. PEG Asparaginase will be given by vein on Week 3 and 6 of each month. You will
      receive methotrexate through a needle through your spine weekly during Month 1 only. Blood
      (about 3 teaspoons) will be drawn for routine tests. You will have a spinal tap with spinal
      fluid tests during the intrathecal methotrexate dose. A spinal tap (also called a lumbar
      puncture) is when a special needle is inserted into the lower back through the space between
      the bones to draw a sample of the fluid that surrounds the spinal cord. You will have a bone
      marrow aspiration at the end of Month 2. To collect a bone marrow aspirate, an area of the
      hip or chest bone is numbed with anesthetic, and a small amount of bone marrow is withdrawn
      through a large needle.

      Consolidation 2 will last for 7 weeks. You will receive vincristine and methotrexate by vein
      every 10 plus or minus 2 days for 5 doses. You will receive PEG Asparaginase by vein in Weeks
      1 and 4. You will receive intrathecal methotrexate in Weeks 1 and 5. You will have a spinal
      tap with spinal fluid tests during the intrathecal methotrexate dose. Blood (about 3
      teaspoons) will be drawn every 2 weeks for routine tests.

      Consolidation 3 (Part A) will last for 4 weeks. You will receive vincristine and Doxorubicin
      by vein in Weeks 1, 2 and 3. Dexamethasone will be taken by mouth on Days 1-7 and Days 15-21.
      You will receive PEG Asparaginase by vein on Week 1. You will receive intrathecal
      methotrexate in Week 1.

      Consolidation 3 (Part B) will last for 4 weeks. You will receive cyclophosphamide by vein in
      Week 1. You will receive cytarabine by vein or as an injection for 4 days in a row in Weeks
      1-2. You will take 6-Thioguanine by mouth every day for the first 2 weeks. You will receive
      intrathecal methotrexate in Weeks 1 and 2. You will receive vincristine by vein on Weeks 3
      and 4. You will receive PEG Asparaginase by vein on Week 3.

      During Consolidation 3 (Part A and B), blood (about 3 teaspoons) will be drawn at least
      weekly for routine tests. Spinal fluid tests will be sent with each intrathecal methotrexate
      dose. Spinal taps will be done during each intrathecal chemotherapy dose

      Once you finish Consolidation, you will proceed to maintenance therapy.

      The Maintenance period for ALL patients will last for 24 months. If you have ALL, you will
      receive vincristine by vein every month. You will take dexamethasone by mouth for 5 days
      every month. You will take 6-Mercaptopurine by mouth once daily. You will take methotrexate
      by mouth every week. You will receive intrathecal methotrexate every 3 months for the first
      12 months of maintenance. You will have a spinal tap with spinal fluid tests during the
      intrathecal methotrexate dose.

      Maintenance for patients with LL will also last for 24 months. If you have LL, you will
      receive vincristine by vein every month. You will take dexamethasone by mouth for 5 days
      every month.

      You will take 6-Mercaptopurine by mouth once daily. You will take methotrexate by mouth every
      week.

      During the Maintenance period, all participants will have blood samples (about 1 to 3
      teaspoons each time) drawn every 3 months for routine tests.

      If you have LL, you will have an additional positron emission tomography (PET) scan and
      computed tomography (CT) scan at the end of the Maintenance period.

      Follow-Up Visits:

      Your study doctor will inform you of your follow-up visits in the clinic. At each follow-up
      visit there will be a physical exam and complete blood count. You will be followed-up for the
      next 3 years after your the last dose of your chemotherapy.

      Length of Study:

      You may remain on study for as long as you are benefiting. You may be taken off study if the
      disease gets worse or comes back during treatment, intolerable side effects occur, new
      information becomes available to your study doctor, if your doctor thinks it is in your best
      interest, or if you do not attend your appointments, which are scheduled at least once every
      3 months.

      This is an investigational study. The chemotherapy drugs used in this study are all FDA
      approved and commercially available. Up to 125 patients will take part in this study. All
      will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2006</start_date>
  <completion_date type="Actual">July 26, 2018</completion_date>
  <primary_completion_date type="Actual">July 26, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-Year Event-Free Survival (EFS)</measure>
    <time_frame>3 Years</time_frame>
    <description>3-year EFS was calculated based on the participants with a complete response (CR). Study regimen considered successful if it exhibits a 3-year EFS rate greater than 60% and response rate no less than 90% with Grade III-IV infectious toxicity rate in induction no more than 33%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 12 years</time_frame>
    <description>Overall Survival defined: Time from date of treatment start until date of death due to any cause or last Follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participants With a Complete Response (CR)</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Complete Response defined as: Bone Marrow blasts &lt;/= 5%, Platelets &gt;/= 100 and an Absolute Neutrophil Count (ANC) &gt;/= 1000</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants Achieving Negative Minimal Residual Disease (MRD)</measure>
    <time_frame>up to 3 months</time_frame>
    <description>To evaluate the prognostic significance of minimal residual disease (MRD) in bone marrow samples of participants who achieved a complete response (CR) at the end of induction (day 29) and at the end of consolidation (day 84) in this group of patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Lymphoblastic Leukemia</condition>
  <condition>Lymphoblastic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Augmented BFM Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction + Maintenance: Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Doxorubicin, Thioguanine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daunorubicin</intervention_name>
    <description>Starting Dose 25 mg/m^2 by vein weekly</description>
    <arm_group_label>Augmented BFM Therapy</arm_group_label>
    <other_name>Cerubidine®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine</intervention_name>
    <description>Starting Dose 2 mg by vein weekly</description>
    <arm_group_label>Augmented BFM Therapy</arm_group_label>
    <other_name>Vincasar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG-asparaginase</intervention_name>
    <description>Starting Dose 2000 International units/m2 by vein in week 1</description>
    <arm_group_label>Augmented BFM Therapy</arm_group_label>
    <other_name>Oncaspar®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrathecal Methotrexate</intervention_name>
    <description>Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid</description>
    <arm_group_label>Augmented BFM Therapy</arm_group_label>
    <other_name>Rheumatrex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Starting Dose 1g/m2 by vein in weeks 1 and 5</description>
    <arm_group_label>Augmented BFM Therapy</arm_group_label>
    <other_name>Cytoxan®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months</description>
    <arm_group_label>Augmented BFM Therapy</arm_group_label>
    <other_name>Cytosar-U®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mercaptopurine</intervention_name>
    <description>Starting Dose 60 mg/m2 by mouth on days 1-14 of each month</description>
    <arm_group_label>Augmented BFM Therapy</arm_group_label>
    <other_name>Purinethol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10
+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3</description>
    <arm_group_label>Augmented BFM Therapy</arm_group_label>
    <other_name>Rheumatrex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>25 mg/m2 by vein in weeks 1, 2 and 3</description>
    <arm_group_label>Augmented BFM Therapy</arm_group_label>
    <other_name>Adriamycin®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thioguanine</intervention_name>
    <description>60 mg/m2 by mouth daily for two weeks</description>
    <arm_group_label>Augmented BFM Therapy</arm_group_label>
    <other_name>Thioguanine Tabloid®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must have precursor-B or T-lymphoblastic leukemia or lymphoblastic lymphoma.

          2. Patients must be untreated or have had only one prior chemotherapy regimen for ALL or
             LL . Previously treated patients will be analyzed separately.

          3. Age between 12 to 40 years old

          4. Patients with Central Nervous System (CNS) disease or testicular disease are eligible.

          5. Intrathecal therapy with cytarabine is allowed prior to registration for patient
             convenience. This is usually done at the time of the diagnostic bone marrow or venous
             line placement to avoid a second lumbar puncture. Systemic chemotherapy must begin
             within 72 hours of the first intrathecal treatment.

          6. Signed informed consent prior to the start of systemic therapy. In the event of
             enrollment of a minor patient, an attempt to obtain assent from the patient must be
             documented, and parental consent must be signed.

          7. Echocardiogram should be done within 72 hours of starting therapy if there are cardiac
             risk factors (e.g., history of hypertension or of myocardial infarction)

          8. Creatinine should be &lt; 3 mg/dL bilirubin &lt; 3 mg/dl unless felt to be due to disease

          9. Zubrod Performance status of &lt;3

         10. Patients who received steroids more than 72 hours prior to study enrollment are
             eligible but will be analyzed separately

        Exclusion Criteria:

          1. Age less than twelve years of age or greater than 40 years.

          2. More than one prior treatment regimen for ALL or LL.

          3. The patient is pregnant or unwilling to practice appropriate birth control.

          4. Presence of the Philadelphia chromosome t(9;22)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael E. Rytting, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 19, 2009</study_first_submitted>
  <study_first_submitted_qc>March 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2009</study_first_posted>
  <results_first_submitted>July 31, 2019</results_first_submitted>
  <results_first_submitted_qc>August 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 10, 2019</results_first_posted>
  <last_update_submitted>August 21, 2019</last_update_submitted>
  <last_update_submitted_qc>August 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute lymphoblastic leukemia</keyword>
  <keyword>acute lymphoblastic lymphoma</keyword>
  <keyword>Leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>6-Thioguanine</keyword>
  <keyword>Cyclophosphamide</keyword>
  <keyword>Cytarabine</keyword>
  <keyword>Daunorubicin</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Methotrexate</keyword>
  <keyword>PEG-L-Asparaginase</keyword>
  <keyword>Vincristine</keyword>
  <keyword>Intrathecal Methotrexate</keyword>
  <keyword>Mercaptopurine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Daunorubicin</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Thioguanine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 18, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT00866749/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: October 2006 - March 2014</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Augmented BFM Therapy</title>
          <description>Induction + Maintenance: Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Doxorubicin, Thioguanine
Daunorubicin: Starting Dose 25 mg/m^2 by vein weekly
Vincristine: Starting Dose 2 mg by vein weekly
PEG-asparaginase: Starting Dose 2000 International units/m2 by vein in week 1
Intrathecal Methotrexate: Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid
Cyclophosphamide: Starting Dose 1g/m2 by vein in weeks 1 and 5
Cytarabine: 75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months
Mercaptopurine: Starting Dose 60 mg/m2 by mouth on days 1-14 of each month
Methotrexate: Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10
+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3
Doxorubicin: 25 mg/m2 by vein in weeks 1, 2 and 3
Thioguanine: 60 mg/m2 by mouth daily for two weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Augmented BFM Therapy</title>
          <description>Induction + Maintenance: Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Doxorubicin, Thioguanine
Daunorubicin: Starting Dose 25 mg/m^2 by vein weekly
Vincristine: Starting Dose 2 mg by vein weekly
PEG-asparaginase: Starting Dose 2000 International units/m2 by vein in week 1
Intrathecal Methotrexate: Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid
Cyclophosphamide: Starting Dose 1g/m2 by vein in weeks 1 and 5
Cytarabine: 75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months
Mercaptopurine: Starting Dose 60 mg/m2 by mouth on days 1-14 of each month
Methotrexate: Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10
+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3
Doxorubicin: 25 mg/m2 by vein in weeks 1, 2 and 3
Thioguanine: 60 mg/m2 by mouth daily for two weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="120"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22" lower_limit="13" upper_limit="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>3-Year Event-Free Survival (EFS)</title>
        <description>3-year EFS was calculated based on the participants with a complete response (CR). Study regimen considered successful if it exhibits a 3-year EFS rate greater than 60% and response rate no less than 90% with Grade III-IV infectious toxicity rate in induction no more than 33%.</description>
        <time_frame>3 Years</time_frame>
        <population>Of the 108 participants who had a complete response, 68 met the definition for 3 year EFS.</population>
        <group_list>
          <group group_id="O1">
            <title>Augmented BFM Therapy</title>
            <description>Induction + Maintenance: Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Doxorubicin, Thioguanine
Daunorubicin: Starting Dose 25 mg/m^2 by vein weekly
Vincristine: Starting Dose 2 mg by vein weekly
PEG-asparaginase: Starting Dose 2000 International units/m2 by vein in week 1
Intrathecal Methotrexate: Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid
Cyclophosphamide: Starting Dose 1g/m2 by vein in weeks 1 and 5
Cytarabine: 75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months
Mercaptopurine: Starting Dose 60 mg/m2 by mouth on days 1-14 of each month
Methotrexate: Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10
+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3
Doxorubicin: 25 mg/m2 by vein in weeks 1, 2 and 3
Thioguanine: 60 mg/m2 by mouth daily for two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>3-Year Event-Free Survival (EFS)</title>
          <description>3-year EFS was calculated based on the participants with a complete response (CR). Study regimen considered successful if it exhibits a 3-year EFS rate greater than 60% and response rate no less than 90% with Grade III-IV infectious toxicity rate in induction no more than 33%.</description>
          <population>Of the 108 participants who had a complete response, 68 met the definition for 3 year EFS.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival</title>
        <description>Overall Survival defined: Time from date of treatment start until date of death due to any cause or last Follow-up.</description>
        <time_frame>Up to 12 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Augmented BFM Therapy</title>
            <description>Induction + Maintenance: Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Doxorubicin, Thioguanine
Daunorubicin: Starting Dose 25 mg/m^2 by vein weekly
Vincristine: Starting Dose 2 mg by vein weekly
PEG-asparaginase: Starting Dose 2000 International units/m2 by vein in week 1
Intrathecal Methotrexate: Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid
Cyclophosphamide: Starting Dose 1g/m2 by vein in weeks 1 and 5
Cytarabine: 75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months
Mercaptopurine: Starting Dose 60 mg/m2 by mouth on days 1-14 of each month
Methotrexate: Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10
+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3
Doxorubicin: 25 mg/m2 by vein in weeks 1, 2 and 3
Thioguanine: 60 mg/m2 by mouth daily for two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall Survival defined: Time from date of treatment start until date of death due to any cause or last Follow-up.</description>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121" lower_limit="0.5" upper_limit="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participants With a Complete Response (CR)</title>
        <description>Complete Response defined as: Bone Marrow blasts &lt;/= 5%, Platelets &gt;/= 100 and an Absolute Neutrophil Count (ANC) &gt;/= 1000</description>
        <time_frame>Up to 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Augmented BFM Therapy</title>
            <description>Induction + Maintenance: Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Doxorubicin, Thioguanine
Daunorubicin: Starting Dose 25 mg/m^2 by vein weekly
Vincristine: Starting Dose 2 mg by vein weekly
PEG-asparaginase: Starting Dose 2000 International units/m2 by vein in week 1
Intrathecal Methotrexate: Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid
Cyclophosphamide: Starting Dose 1g/m2 by vein in weeks 1 and 5
Cytarabine: 75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months
Mercaptopurine: Starting Dose 60 mg/m2 by mouth on days 1-14 of each month
Methotrexate: Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10
+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3
Doxorubicin: 25 mg/m2 by vein in weeks 1, 2 and 3
Thioguanine: 60 mg/m2 by mouth daily for two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With a Complete Response (CR)</title>
          <description>Complete Response defined as: Bone Marrow blasts &lt;/= 5%, Platelets &gt;/= 100 and an Absolute Neutrophil Count (ANC) &gt;/= 1000</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Achieving Negative Minimal Residual Disease (MRD)</title>
        <description>To evaluate the prognostic significance of minimal residual disease (MRD) in bone marrow samples of participants who achieved a complete response (CR) at the end of induction (day 29) and at the end of consolidation (day 84) in this group of patients.</description>
        <time_frame>up to 3 months</time_frame>
        <population>Of the 108 participants who achieved a complete response (CR), 60 participants were MRD negative on day 29 and an additional 27 participants were MRD negative on day 84 for a total 87 MRD negative participants on day 84</population>
        <group_list>
          <group group_id="O1">
            <title>Augmented BFM Therapy</title>
            <description>Induction + Maintenance: Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Doxorubicin, Thioguanine
Daunorubicin: Starting Dose 25 mg/m^2 by vein weekly
Vincristine: Starting Dose 2 mg by vein weekly
PEG-asparaginase: Starting Dose 2000 International units/m2 by vein in week 1
Intrathecal Methotrexate: Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid
Cyclophosphamide: Starting Dose 1g/m2 by vein in weeks 1 and 5
Cytarabine: 75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months
Mercaptopurine: Starting Dose 60 mg/m2 by mouth on days 1-14 of each month
Methotrexate: Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10
+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3
Doxorubicin: 25 mg/m2 by vein in weeks 1, 2 and 3
Thioguanine: 60 mg/m2 by mouth daily for two weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Achieving Negative Minimal Residual Disease (MRD)</title>
          <description>To evaluate the prognostic significance of minimal residual disease (MRD) in bone marrow samples of participants who achieved a complete response (CR) at the end of induction (day 29) and at the end of consolidation (day 84) in this group of patients.</description>
          <population>Of the 108 participants who achieved a complete response (CR), 60 participants were MRD negative on day 29 and an additional 27 participants were MRD negative on day 84 for a total 87 MRD negative participants on day 84</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with CR and MRD negative on Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with CR and MRD negative on day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Participants were assessed through study completion, for up to 3 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Augmented BFM Therapy</title>
          <description>Induction + Maintenance: Daunorubicin, Vincristine, PEG-asparaginase, Intrathecal Methotrexate, Cyclophosphamide, Cytarabine, Mercaptopurine, Doxorubicin, Thioguanine
Daunorubicin: Starting Dose 25 mg/m^2 by vein weekly
Vincristine: Starting Dose 2 mg by vein weekly
PEG-asparaginase: Starting Dose 2000 International units/m2 by vein in week 1
Intrathecal Methotrexate: Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid
Cyclophosphamide: Starting Dose 1g/m2 by vein in weeks 1 and 5
Cytarabine: 75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months
Mercaptopurine: Starting Dose 60 mg/m2 by mouth on days 1-14 of each month
Methotrexate: Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10
+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3
Doxorubicin: 25 mg/m2 by vein in weeks 1, 2 and 3
Thioguanine: 60 mg/m2 by mouth daily for two weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive Heart Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Double vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Cramps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" events="15" subjects_affected="7" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Gallbladder Obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Gastroparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Pneumoperitoneum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Cytomegalovirus antigen positive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Generalized Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Groin Abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Knee Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="29" subjects_affected="22" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="51" subjects_affected="30" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated Alanine Aminotransferase</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Avascular Necrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Osteoprosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Central Nervous System, White matter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Cognitive Disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Leukoencephalopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety/depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Renal Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Vaginal Herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Pleuritic Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Pulmonary Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Respiratory Syncytial Virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Striae</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricualr arrhythmia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="23" subjects_affected="19" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="38" subjects_affected="29" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity</sub_title>
                <counts group_id="E1" events="25" subjects_affected="23" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenic Fever</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="138" subjects_affected="70" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fibrinogen</sub_title>
                <counts group_id="E1" events="44" subjects_affected="43" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Elevated Alanine Aminotransferase</sub_title>
                <counts group_id="E1" events="78" subjects_affected="25" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Lipase</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="22" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="87" subjects_affected="57" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="11" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy motor</sub_title>
                <counts group_id="E1" events="21" subjects_affected="19" subjects_at_risk="120"/>
              </event>
              <event>
                <sub_title>Neuropathy sensor</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="29" subjects_affected="22" subjects_at_risk="120"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Andreeff MD./Professor</name_or_title>
      <organization>The University of Texas MD Anderson Cancer Center</organization>
      <phone>713-792-7261</phone>
      <email>mandreeff@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

